Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test strategy may spare kidney patients from unnecessary biopsies

NCT ID NCT04774575

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using non-invasive blood biomarkers to guide when to perform a biopsy is as safe as doing routine biopsies at set times in kidney transplant recipients. 342 patients were randomly assigned to either a biomarker-guided group or a routine biopsy group. The goal was to see if the biomarker approach could reduce the number of biopsies without missing signs of organ rejection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
biomarker-guided strategy (non-invasive blood tests)
What this could lead to
If successful, this approach could reduce the need for painful and risky routine biopsies in kidney transplant patients, making follow-up safer and more comfortable.
What could go wrong
This is a completed trial, but the strategy may not detect all cases of rejection, and results may not apply to all transplant centers or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

342 people

The number who actually took part.

Started

Dec 2021

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. All men and women, age ≥18 years old. 2. Subject must be a recipient of a single renal transplant from a deceased or living donor. 3. Subject is willing and able to provide signed written informed consent and willing to comply with study procedures 4. Women of Childbearing Potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal \[defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL\]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of clinical trial Exclusion Criteria: 1. Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive blood PCR result at the moment of transplant). 2. Subjects with known human immunodeficiency virus (HIV) infection. 3. Patients with active systemic infection that requires the continued use of antibiotics. 4. Patients with neoplasia except localized skin cancer receiving appropriate treatment. 5. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment. 6. Subjects who are legally detained in an official institution. 7. Primary non-function or early graft loss due to mechanical/surgical complications. 8. Death within the first 6 months after transplantation. 9. Any condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient 10. History of multi-organ transplant (interference with rejection natural history).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal transplantation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bellvitge University Hospital

    Barcelona, 08907, Spain

  • Charité-Universitätsmedizin,

    Berlin, 10117, Germany

  • Charité-Universitätsmedizin, Berlin

    Berlin, 10117, Germany

  • Geneva University Hospitals

    Geneva, Canton of Geneva, 1205, Switzerland

  • Nantes Hospital

    Nantes, 44000, France

  • Necker Hospital, Paris

    Paris, Île-de-France Region, 75015, France

  • Saint-Louis Hospital, Paris

    Paris, Île-de-France Region, 75010, France

  • Vall d'Hebron Hospital

    Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.